Bispecific checkpoint inhibitor antibodies
US11492407B2 · kind B2 · utility
0Cited by
133References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2019 |
| Grant date | Nov 8, 2022 |
| Priority date | — |
| Expiry date | Oct 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.